Literature DB >> 17344093

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system.

Dorothea Sizmann1, Claudia Boeck, Juergen Boelter, Daniela Fischer, Marion Miethke, Stefan Nicolaus, Markus Zadak, Reiner Babiel.   

Abstract

BACKGROUND: HCV RNA is commonly recognized as key parameter for reliable diagnosis and treatment monitoring of HCV infection. Determination of blood HCV RNA concentrations reduces the pre-seroconversion period in the diagnosis of HCV infection and supports management of interferon alpha-based therapies of chronic HCV infection. OBJECTIVES AND STUDY
DESIGN: The COBAS AmpliPrep/COBAS TaqMan HCV Test combines automated extraction of nucleic acids on the COBAS AmpliPrep Instrument with real-time PCR on the COBAS TaqMan Analyzer, thus greatly reducing hands-on time during sample preparation and amplification/detection. The test, which is calibrated to the 1st International HCV WHO Standard, was evaluated for sensitivity, dynamic range, precision, matrix equivalence, genotype inclusivity, interfering substances, diagnostic and analytical specificity, as well as for correlation with two other commercial tests for HCV RNA quantification.
RESULTS: The COBAS AmpliPrep/COBAS TaqMan HCV Test demonstrated a >6-log dynamic range of 43-6.90 E+7 IU/mL, a sensitivity (95% hit rate) of at least 15 IU/mL for HCV WHO Standard and a comparable quantification of genotypes 1-6. HCV quantification results were in good correlation with those obtained by the COBAS AMPLICOR HCV MONITOR Test v2.0 and the VERSANT HCV RNA 3.0 test.
CONCLUSIONS: The fully automated COBAS AmpliPrep/COBAS TaqMan HCV Test excellently accomplishes the requirements for highly sensitive detection and reliable quantification of HCV in clinical samples and thus improves therapy monitoring and management of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344093     DOI: 10.1016/j.jcv.2006.12.021

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  25 in total

1.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.

Authors:  Ingmar Mederacke; Birgit Bremer; Benjamin Heidrich; Janina Kirschner; Katja Deterding; Thomas Bock; Karsten Wursthorn; Michael P Manns; Heiner Wedemeyer
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Genotyping of hepatitis C virus by sequence analysis of the amplicon from the Roche Cobas AmpliPrep/Cobas TaqMan viral load assay.

Authors:  Todd S Laughlin; Bonnie Nuccie; Paul G Rothberg
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

4.  A capillary based chemiluminscent multi-target immunoassay.

Authors:  Yuan-Cheng Cao
Journal:  J Fluoresc       Date:  2015-03-04       Impact factor: 2.217

5.  Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.

Authors:  S Pas; R Molenkamp; J Schinkel; S Rebers; C Copra; S Seven-Deniz; D Thamke; R J de Knegt; B L Haagmans; M Schutten
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

6.  Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.

Authors:  Valerianna K Amorosa; Anne Luetkemeyer; Minhee Kang; Victoria A Johnson; Triin Umbleja; David W Haas; Suria Yesmin; Matthew C Bardin; Ray T Chung; Beverly Alston-Smith; Pablo Tebas; Marion G Peters
Journal:  HIV Clin Trials       Date:  2013 Nov-Dec

7.  Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Taniai; Shigeru Otaguro; Mosaburo Kainuma; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  BMC Gastroenterol       Date:  2010-04-16       Impact factor: 3.067

8.  Dental problems delaying the initiation of interferon therapy for HCV-infected patients.

Authors:  Yumiko Nagao; Michio Sata
Journal:  Virol J       Date:  2010-08-17       Impact factor: 4.099

9.  Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples.

Authors:  Tony Bruns; Katrin Steinmetzer; Eugen Ermantraut; Andreas Stallmach
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

10.  Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total nucleic acid isolation and COBAS taqman hepatitis C virus analyte-specific reagent.

Authors:  Michael S Forman; Alexandra Valsamakis
Journal:  J Mol Diagn       Date:  2008-02-14       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.